Expanding our reach: Nostrum Biodiscovery in Boston and Japan
This autumn, Nostrum Biodiscovery took its drug discovery engine to two key markets: the United States and Japan.
Boston: Discovery on Target
At the end of September, our co-founder and CSO Víctor Guallar spoke at Discovery on Target in Boston. He presented our E3 ligase and molecular glue/degrader screening workflows, already experimentally validated with two leading biotech companies and built on our proprietary platforms:
- PELE®, our protein-ligand simulation platform, with GluePELE and PELETAC for molecular glues and PROTACs
- TPD-Suite® for targeted protein degradation
Víctor was joined by our Boston-based business development team, who met with partners working on challenging targets.
Japan: Osaka, Shonan iPark and BioJapan
In early October, our General Manager Marie-Eve Beaulieu joined the EU-Japan Centre for Industrial Cooperation in Osaka, meeting established pharma companies and early-stage projects, and then presented our poster at Shonan Health Innovation Park (Shonan iPark).
The message: Nostrum Biodiscovery is a drug discovery engine. We are a computational drug discovery technology developer, and we solve drug design problems on proprietary platforms we build ourselves:
- Target evaluation: our YGGDRASIL knowledge graph integrates biological, genetic, structural and chemical evidence to prioritize targets and de-risk decisions early
- Hit finding and lead optimization: PELE® and our AI tools, plus dedicated platforms for new modalities: XNAHub®, ChaRNABERT, TPD-Suite®, GluePELE and PELETAC
The trip continued at BioJapan (7-9 October, Yokohama). Thank you to the EU-Japan Centre for the organization and the connections. Follow-ups are already underway.
Working on a challenging target in the US or Asia? Get in touch to arrange a conversation with our team.
